|
Sunday, 08/01/2010
|
Quantile Regression Approach to the Location-Scale Model
Hyokyoung (Grace) Hong, Baruch College, CUNY
2:35 PM
|
Asymptotic Theory for Fractionally Integrated Asymmetric Power ARCH Models
Kazuhiko Shinki, Wayne State University; Henry Zhengjun Zhang, University of Wisconsin-Madison
2:35 PM
|
Tests of Trend Between Disease Outcomes and Ordinal Covariates
Naomi Brownstein, The University of North Carolina
3:20 PM
|
A Power Comparison of Generalized Additive Models and the Spatial Scan Statistic in a Case-Control Setting
Robin Young, Boston University; Janice Weinberg, Boston University; Veronica Vieira, Boston University; Al Ozonoff, Boston University School of Public Health; Thomas Webster, Boston University
4:05 PM
|
A Parametric Test for Correlated Time-to-Event Data with a Failure Rate Change
Gang Han, Moffitt Cancer Center & Research Institute; Ji-Hyun Lee, Moffitt Cancer Center & Research Institute
4:05 PM
|
Costationarity of Locally Stationary Time Series
Guy Nason, University of Bristol; Alessandro Cardinali, University of Bristol
4:25 PM
|
A Comparison of Several Methods for Analyzing Data from Thorough QT Studies
Hong Tian, Johnson & Johnson; Wenqian Qiao, Rutgers University; Jaya Natarajan, Johnson & Johnson
4:25 PM
|
Two-Stage Adaptive Design for Bioequivalence: Methods and Application
Yi-Lin Chiu, Abbott Global Pharmaceuticals Research and Development; Yannis Jemiai, Cytel Inc.; Charles Locke, Abbott Laboratories; Pralay Senchaudhuri, Cytel Inc.
4:25 PM
|
Teaching a Second Statistics Course for QBIC: A Special Program at Florida International University
Ramon Gomez, Florida International University
4:35 PM
|
Calibrated Power Model Selection
Hugh Crews, University of North Carolina Wilmington; Clayton Barker, SAS Institute
5:05 PM
|
Having It Both Ways: Teaching Statistics for Online or Hardcopy Note-Taking
Nancy Pfenning, University of Pittsburgh
5:05 PM
|
|
Monday, 08/02/2010
|
Power and Robustness of Nonparametric Covariate Adjustment Methods for Ordinal Data
Muhtarjan Osman, North Carolina State University; Wei Tian, Inspire Pharmaceuticals
|
Establishing Sample Size in Clinical Trials Having Multiple Hypotheses
Alan Barry Davis, Pharmanet Development Group, Inc.; Mary M. Poole, Pharmanet Development Group, Inc.; Young Kim, Pharmanet Development Group, Inc.
|
Analysis of Statistical Tests to Compare Cumulative Proportion of Responders for Pain Data in Clinical Trials
Song Wang, PPD, Inc.
|
Comparison of Power for ANCOVA Models Based on Central Tendency versus Nonparametric Analysis of Cumulative Responders for Clinical Trials with Continuous Response Endpoints
Kevin L. Lawson, PPD, Inc.
|
WITHDRAWN: Functional Mixed-Effects Modeling of Electroencephalographic (EEG) Data
Shubhankar Ray, Merck & Co., Inc.
|
Using Pilot Study for Clinical Study Planning
Hongbin Gu, The University of North Carolina at Chapel Hill; Xiaofei Wang, Duke University
|
Relative Power and Robustness of Mixed Model, GEE, and MMRM Analysis of Alzheimer's Disease Treatment Trials
Steven D. Edland, University of California, San Diego
8:35 AM
|
Futility Assessment Utilizing Conditional Power in a Phase III Clinical Trial
Yan Sun, Amgen Inc.
8:35 AM
|
Sample Size and Power Considerations for Futility Trial Design: Buying Power vs. Spending Beta
Thomas Dobbins, Merck & Co., Inc.
8:50 AM
|
Multinational Clinical Trials: A Perspective from Latin America
Carolina Cernadas, Schering Plough Argentina
8:55 AM
|
Evaluating personalized treatment strategies: Subset analyses do not avoid the loss of power due to subgroups with no treatment effect
Werner Vach, Institute of Medical Biometry and Medical Informatics; Rene dePont Christensen, University of Southern Denmark; Oke Gerke, Odense University Hospital
8:55 AM
|
Optimization of Error Spending Approach in Clinical Trials
Michael Baron, The University of Texas at Dallas; Yi Zhong, The University of Texas at Dallas
9:05 AM
|
Power Under Local Alternatives for Generalized Estimating Equations
Zhigang Li, Columbia University
9:15 AM
|
Conditional Power and Predictive Power Approaches to Interim Monitoring in Equivalence Trials
Xiaojiang Zhan, Merck & Co., Inc.
9:20 AM
|
Evaluation of Common Statistical Methods in Randomized Delayed-Start Design of Progression Disease Clinical Trials
Bongin Yoo, Bristol-Myers Squibb; Thomas Kelleher, Bristol-Myers Squibb
9:35 AM
|
Two-Stage Designs with Additional Futility Tests for Phase II Clinical Trials with Heterogeneous Patient Populations
Myron N. Chang, University of Florida; Sin-Ho Jung, Duke University
10:05 AM
|
Achieving the Benefits of Both an Internal Pilot and Interim Analysis in Small Samples
John A. Kairalla, University of Florida; Keith E. Muller, University of Florida; Christopher S. Coffey, The University of Iowa
10:35 AM
|
Automatic Diagnostic Checking for Vector Autoregressions
Ignacio Lobato, ITAM; Juan Carlos Escanciano, Indiana University; Lin Zhu, Indiana University
10:50 AM
|
The Complexities of a Multivariate Power Analysis: Possible Finite Solutions to an Infinite Problem
Kathryn Mary Irvine, Montana State University; Daniel Sarr, Klamath Network - National Park Service; Eric Dinger, Klamath Network - National Park Service
10:55 AM
|
Sample Size Requirement in Clustered Matched-Pair Design for Noninferiority Test
Jun-mo Nam, National Cancer Institute
11:20 AM
|
Improved Survival Modeling Using a Reduced Piecewise Exponential Approach
Gang Han, Moffitt Cancer Center & Research Institute; Michael J. Schell, Moffitt Cancer Center; Jongphil Kim, Moffitt Cancer Center & Research Institute
12:05 PM
|
Adaptive Sample Size Re-estimation When Interim Results Are Promising
Cyrus R. Mehta, Cytel Inc.
2:25 PM
|
Testing a Primary and a Secondary Endpoint in a Group Sequential Design
Ajit C. Tamhane, Northwestern University; Cyrus R. Mehta, Cytel Inc.; Lingyun Liu, Cytel Inc.
2:25 PM
|
Assessing the Impact of Partial Monitoring on Power Within Clinical Trials
Joe William Bero, Boston Scientific Corporation
2:45 PM
|
Choice of Multiple Comparison Procedure in Two Pivotal Clinical Trials for Approval of a New Pharmaceutical Product: Power and Aesthetics
Brian L. Wiens, Alcon Laboratories, Inc.; Alex Dmitrienko, Eli Lilly and Company
3:05 PM
|
How to Estimate Measurement Error Variance Associated with Ancestry Proportion Estimates
Jasmin Divers, Wake Forest University Health Sciences; David T. Redden, The University of Alabama at Birmingham; Raymond J. Carrol, Texas A&M University; David B. Allison, The University of Alabama at Birmingham
3:05 PM
|
|
Tuesday, 08/03/2010
|
A New Method for the Comparison of Survival Distributions
Xun Lin, Pfizer Global Research and Development; Qiang Xu, FDA
|
Impact of Relying on Sample Variance-Covariance Estimate on Prediction Accuracy and Statistical Power of Hypothesis Testing When n << p
Peter H. Hu, Merck & Co., Inc.; Yue Wang, Merck & Co., Inc.; Jared Lunceford, Merck & Co., Inc.
|
Power in the Case of Extreme Bimodal Distribution: Analysis of Delirium/Coma-Free Days in the ICU
Jennifer L. Thompson, Vanderbilt University; Ayumi Shintani, Vanderbilt University
|
Analyzing Gene Expression Data Using a Self-Contained Gene Set Enrichment Analysis Method
Jiawei Liu, Georgia State University
|
What Will Happen to the Power If Dependent and Independent Variables Are Switched?
Youngju Pak, University of Missouri-Columbia; Wade Justin Davis, University of Missouri-Columbia
|
Framing Specific Hypotheses: What's the Alternative?
Daniel Theodore Kaplan, Macalester College
9:20 AM
|
Wavelet-Based Power Transformation for Long Memory Regression Models with non-Gaussian Errors
Kyungduk Ko, Boise State University
9:50 AM
|
Improved Statistical Modeling of Power Outages During Hurricanes in the United States
Roshi Nateghi, The Johns Hopkins University; Seth Guikema, The Johns Hopkins University; Steven Quiring, Texas A&M University
9:50 AM
|
Random Delayed Effects and the Power of the Unweighted Log-Rank Test in Survival Trials
Jonathan Siegel, Bristol-Myers Squibb
10:35 AM
|
A Power Analysis of Misspecified Types of Time-Varying Covariates for Generalized Method of Moments Applied to Binary Responses
Trent Lalonde, University of Northern Colorado; Jeffrey R. Wilson, The University of Utah
10:50 AM
|
Sample-Size Calculation for Time-to-Event Outcome with Treatment Lag Effect
Yulei Zhang, Columbia University; Tai-Tsang Chen, Bristol-Myers Squibb/Columbia University
11:20 AM
|
Asymptotically Similar Unit Root Tests in the Presence of Autocorrelated Errors
Michalis Stamatogiannis, University of Groningen
2:35 PM
|
Sample Size Determination in Two-Sided Distribution-Free Treatment vs. Control Multiple Comparisons
Chunpeng Fan, sanofi-aventis; Donghui Zhang, sanofi-aventis
2:50 PM
|
Genetic Matching for Robust and Powerful Detection of Gene-Gene Interactions in Case-Control Studies
Samsiddhi Bhattacharjee, National Cancer Institute; Nilanjan Chatterjee, National Cancer Institute
2:50 PM
|
Assessing the Improved Discriminatory Power of a New Biomarker in Prognostic Models
Mei Liu, MD Anderson Cancer Center; Carol J. Etzel, MD Anderson Cancer Center; Asha Kapadia, The University of Texas School of Public Health
3:05 PM
|
On Optimal Grouping Strategies Using Parallel Gatekeeping Procedures
Haiyuan Zhu, Forest Research Institute
3:20 PM
|
|
Wednesday, 08/04/2010
|
Assessing the Impact of Tumor Heterogeneity on Powering Microarray Signature Discovery
Timothy Scott Davison, Almac Diagnostics; Sian Dibben, Almac Diagnostics; Janet Taylor, Almac Diagnostics; Robert J. Holt, Almac Diagnostics; Paul J. Kelly, Belfast Health and Social Care Trust; Ian Paul, Queen's University Belfast; Peter Kerr, Almac Diagnostics; Dean A. Fennell, Queen's University Belfast; Jacqueline A. James, Queen's University Belfast; Richard D. Kennedy, Almac Diagnostics
|
Threshold-Free Cluster Enhancement (TFCE): Improving Power and Stability of Cluster Size Inference in Brain Imaging
Thomas E. Nichols, University of Warwick
8:35 AM
|
Comparison of Statistical Models Adjusting for Baseline in the Analysis of Thorough QT/QTc Studies
Guowen (Gordon) Sun, sanofi-aventis; Hui Quan, sanofi-aventis
8:35 AM
|
Statistical Power for Genome-Wide Association Analysis of Case-Control Studies on Rare Serious Adverse Drug Reactions
Wencan Zhang, Takeda Global Research & Development Center, Inc.; Tatsuya Ando, Takeda Pharmaceutical Company Limited; Robert Dillard, Takeda Global Research & Development Center, Inc.; Leonardo Sahelijo, Takeda Global Research & Development Center, Inc.; Shyh-yuh Liou, Takeda Pharmaceutical Company Limited; Hiroyoshi Toyoshiba, Takeda Pharmaceutical Company Limited
10:50 AM
|
An Adaptive Futility Monitoring Method with Time-Varying Conditional Power Boundary
Ying Zhang, The University of Iowa; William Clarke, The University of Iowa
10:55 AM
|
A Theory for Testing Hypotheses Under Covariate-Adaptive Randomization
Jun Shao, University of Wisconsin-Madison; Xinxin Yu, University of Wisconsin-Madison; Bob Zhong, Johnson & Johnson
10:55 AM
|
Considerations in Vaccine Lot Consistency Trials
Xiao Sun, Merck Research Laboratories; Joshua Chen, Merck Research Laboratories
11:05 AM
|
Maximum Entropy Spectral Analysis to Time Series with Missing Value
Aladdin Shamilov, Anadolu University; Cigdem Giriftinoglu, Anadolu University
11:20 AM
|
Hierarchical Gaussian Power Prior Models for Adaptive Incorporation of Historical Information in Clinical Trials
Bradley P. Carlin, University of Minnesota; Brian P. Hobbs, University of Minnesota; Daniel Sargent, Mayo Clinic; Sumithra Mandrekar, Mayo Clinic
2:05 PM
|
Identification of Power Distribution Mixtures Through Regression of Exponentials
Wen-Jang Huang, National University of Kaohsiung
2:50 PM
|
Adding a Prediction Interval Futility Analysis to a Group Sequential Trial
John Loewy, ARIAD Pharmaceuticals; David Dorer, ARIAD Pharmaceuticals
3:25 PM
|
Effect of Patient Allocation Schemes on the Power of a Test for Treatment Effect
Fanni Natanegara, Eli Lilly and Company; Christel Faes, Hasselt University; Geert Molenberghs, I-BioStat; Craig Mallinckrodt, Eli Lilly and Company
3:35 PM
|
|
Thursday, 08/05/2010
|
Sample Size Re-estimation for a Time-to-event Endpoint Based on Stratified Analysis
Liang Chen, Pfizer Inc.
8:50 AM
|
A Weighted Logarithmic Distribution: Stretching the Long Tail
Michael Terry Anderson, The University of Texas at San Antonio; Ram C. Tripathi, The University of Texas at San Antonio
9:05 AM
|
Sample Size and Power for Truncated Bivariate Normal Distribution
Sourav Santra, Takeda Pharmaceutical Company Limited
9:05 AM
|
Selecting Covariance Structures in 3, 4, and 6 Period PK and PD Crossover Trials
Deborah Panebianco, Merck & Co., Inc.; Tom Bradstreet, Merck & Co., Inc.; Andrea Maes, Novartis Pharmaceuticals Corporation; Lata Maganti, Merck & Co., Inc.
9:20 AM
|
A Comparison on FWE-Type Multiple Comparison Procedures
Rosa Arboretti, University of Padova; Livio Corain, University of Padova
9:35 AM
|
Power and Sample Size Calculations for Drug Exposure Registries Using Exact Methods
Paul Schuette, FDA; Eugenio Andraca-Carrera, FDA; Matthew Jackson, FDA; Benjamin Neustifter, FDA
9:35 AM
|
Considerations for Design and Data Analysis of Adaptive Superiority/Noninferiority Cardiovascular Trials
Hui Quan, sanofi-aventis; Mingyu Li, Celgene Corporation; Peng-Liang Zhao, sanofi-aventis; Meehyung Cho, sanofi-aventis; Ji Zhang, Sanofi-Aventis; Yujun Wu, Sanofi-Aventis
10:35 AM
|
Sample Size Planning to Obtain Narrow Confidence Intervals for the RMSEA
Ken Kelley, University of Notre Dame; Keke Lai, University of Notre Dame
10:50 AM
|
Power Analyses for Negative Binomial Models with Application to Multiple Sclerosis Clinical Trials
Mallikarjuna Rettiganti, The Ohio State University; Haikady Nagaraja, The Ohio State University
10:50 AM
|
Quantifying the Cost in Power of Ignoring Covariate Imbalances in Clinical Trial Randomization
Jody Dyan Ciolino, Medical University of South Carolina; Wenle Zhao, Medical University of South Carolina; Yuko Y. Palesch, Medical University of South Carolina; Renee' Martin, Medical University of South Carolina
10:50 AM
|
A Simulation Study to Compare Modeling Approaches for Dose Proportionality Data
Andrea Maes, Novartis Pharmaceuticals Corporation; Wen-Lin Luo, Merck & Co., Inc.; Yu Ding, Merck Research Laboratories; Deborah Panebianco, Merck & Co., Inc.
11:05 AM
|
A Simulation Study to Evaluate Sample Size and Power for a Trial to Develop a Prediction Rule Using Machine Learning Methods
Radha Railkar, Merck & Co., Inc.; Matthew Wiener, Merck & Co., Inc.; Leonidas Carayannopoulos, Merck & Co., Inc.
11:20 AM
|
Analysis of Non-Negative, Continuously Distributed Data with Excessive Zeros
Huiling Li, sanofi-aventis; Lynn Wei, sanofi-aventis; Hui Quan, sanofi-aventis; Nanshi Sha, Columbia University
11:50 AM
|
|